Targeting the cytoskeleton and extracellular matrix in cardiovascular disease drug discovery

References

• World Health Organization. n.d. About cardiovascular diseases. [Cited 2021 May 16]. Available from: https://www.who.int/cardiovascular_diseases/about_cvd/en
   Google Scholar
• World Heart Federation. n.d. CVD Advocacy Toolkit.” cited 2021 May 16. https://www.world-heart-federation.org/wp-content/uploads/2017/05/WHF9421_Advocacy_toolkit__PDF-1.pdf
   Google Scholar
• Aspegren K. n.d. “Heart disease and stroke statistics — 2020 update: a report from the American Heart Association: what’s new this year?. 12.
   Google Scholar
• Birger M, Kaldjian AS, Roth GA, et al. Spending on cardiovascular disease and cardiovascular risk factors in the United States: 1996-2016. Circulation. 2021 April;144(4):271–282. CIRCULATIONAHA.120.053216.
   PubMed Web of Science ®Google Scholar
• Khomtchouk BB, Tran D-T, Vand KA, et al. Cardioinformatics: the nexus of bioinformatics and precision cardiology. Brief Bioinform. 2020;21(6):2031–2051.
   PubMed Web of Science ®Google Scholar
• Thomas TH, and Advani A. Inflammation in cardiovascular disease and regulation of the actin cytoskeleton in inflammatory cells: the actin cytoskeleton as a target. 2006;18:165–82.
   Google Scholar
• Stupack DG, Cheresh DA. Apoptotic cues from the extracellular matrix: regulators of angiogenesis. Oncogene. 2003;22(56):9022–9029.
   PubMed Web of Science ®Google Scholar
• Byron A, Frame MC. Adhesion protein networks reveal functions proximal and distal to cell-matrix contacts. Curr Opin Cell Biol. 2016;39(April):93–100.
   PubMedGoogle Scholar
• Calderwood DA, Campbell ID, Critchley DR. Talins and kindlins: partners in integrin-mediated adhesion. Nat Rev Mol Cell Biol. 2013;14(8):503–517.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. Cardiac fibrosis: cell biological mechanisms, molecular pathways and therapeutic opportunities. Mol Aspects Med. February 2019a;65:70–99.
   PubMed Web of Science ®Google Scholar
• Kato S, Saito N, Kirigaya H, et al. Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int J Cardiol. 2015;191(July):314–319.
   PubMedGoogle Scholar
• Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev. 2012;92(2):635–688.
   PubMed Web of Science ®Google Scholar
• Lampi MC, Reinhart-King CA. targeting extracellular matrix stiffness to attenuate disease: from molecular mechanisms to clinical trials. Sci Transl Med. 2018;10(422):eaao0475.
   PubMed Web of Science ®Google Scholar
• Ponticos M, Smith BD. Extracellular matrix synthesis in vascular disease: hypertension, and atherosclerosis. J Biomed Res. 2014 January;28(1):25–39.
   PubMedGoogle Scholar
• Tayebjee MH, MacFadyen RJ, Lip GYH. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension? J Hypertens. 2003;21(12):2211–2218.
   PubMed Web of Science ®Google Scholar
• Holm Nielsen S, Jonasson L, Kalogeropoulos K, et al. Exploring the role of extracellular matrix proteins to develop biomarkers of plaque vulnerability and outcome. J Intern Med. 2020;287(5):493–513.
   PubMed Web of Science ®Google Scholar
• Schroen B, Heymans S, Umesh Sharma W, et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ Res. 2004;95(5):515–522.
   PubMed Web of Science ®Google Scholar
• Wang D, Oparil S, Feng JA, et al. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide–null mouse. Hypertension. 2003;42(1):88–95.
   PubMed Web of Science ®Google Scholar
• Belmadani S, Bernal J, Wei C-C, et al. A Thrombospondin-1 antagonist of transforming growth factor-β activation blocks cardiomyopathy in rats with diabetes and elevated Angiotensin II. Am J Pathol. 2007;171(3):777–789.
   PubMed Web of Science ®Google Scholar
• Shimojo N, Hashizume R, Kanayama K, et al. Tenascin-C May accelerate cardiac fibrosis by activating macrophages via the integrin ΑVβ3/nuclear factor–ΚB/interleukin-6 axis. Hypertension. 2015;66(4):757–766.
   PubMed Web of Science ®Google Scholar
• Ma WF, Hodonsky CJ, Turner AW, et al. Enhanced single-cell RNA-seq workflow reveals coronary artery disease cellular cross-talk and candidate drug targets. Atherosclerosis. 2022 January 1;340. 12–22. https://doi.org/https://doi.org/10.1016/j.atherosclerosis.2021.11.025
   PubMed Web of Science ®Google Scholar
• Socha MJ, Manhiani M, Said N, et al. Secreted protein acidic and rich in cysteine deficiency ameliorates renal inflammation and fibrosis in angiotensin hypertension. Am J Pathol. 2007;171(4):1104–1112.
   PubMed Web of Science ®Google Scholar
• Strandjord TP, Madtes DK, Weiss DJ, et al. Collagen accumulation is decreased in SPARC-null mice with bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 1999;277(3):L628–35.
   Web of Science ®Google Scholar
• Mavroidis M, Capetanaki Y. Extensive induction of important mediators of fibrosis and dystrophic calcification in desmin-deficient cardiomyopathy. Am J Pathol. 2002;160(3):943–952.
   PubMed Web of Science ®Google Scholar
• Abdelaziz Mohamed I, Gadeau A-P, Hasan A, et al. Osteopontin: a promising therapeutic target in cardiac fibrosis. Cells. 2019;8(12):1558.
   Web of Science ®Google Scholar
• Matsui Y, Jia N, Okamoto H, et al. Role of osteopontin in cardiac fibrosis and remodeling in Angiotensin II-induced cardiac hypertrophy. Hypertension. 2004;43(6):1195–1201.
   PubMed Web of Science ®Google Scholar
• Harvey A, Montezano AC, Lopes RA, et al. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32(5):659–668.
   PubMed Web of Science ®Google Scholar
• Thenappan T, Chan SY, Kenneth Weir E. Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol. 2018;315(5):H1322–31.
   PubMed Web of Science ®Google Scholar
• Lai W-F, Wong W-T, Lai, Wing-Fu, and Wing-Tak Wong. Roles of the actin cytoskeleton in aging and age-associated diseases. Ageing Res Rev. 2020;58(March):101021.
   PubMedGoogle Scholar
• Feihl F, Liaudet L, Levy BI, et al. Hypertension and microvascular remodelling. Cardiovasc Res. 2008;78(2):274–285.
   PubMed Web of Science ®Google Scholar
• Cai Z, Gong Z, Zhiqing L, et al. Vascular extracellular matrix remodeling and hypertension. Antioxid Redox Signal. 2021;34(10):765–783.
   PubMed Web of Science ®Google Scholar
• Intengan HD, and Schiffrin EL. Vascular remodeling in hypertension. 2001;7:581–587.
   Google Scholar
• Lemarié CA, Tharaux P-L, Lehoux S. Extracellular matrix alterations in hypertensive vascular remodeling. J Mol Cell Cardiol. 2010;48(3):433–439.
   PubMed Web of Science ®Google Scholar
• Tuder RM. Pulmonary vascular remodeling in pulmonary hypertension. Cell Tissue Res. 2017;367(3):643–649.
   PubMed Web of Science ®Google Scholar
• Pang W, Zhang Z, Zhang Y, et al. Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension. J Thromb Thrombolysis. 2020 November;52(1):48–58.
   PubMed Web of Science ®Google Scholar
• Chelladurai P, Seeger W, Pullamsetti SS. Matrix metalloproteinases and their inhibitors in pulmonary hypertension. Eur Respir J. 2012;40(3):766–782.
   PubMed Web of Science ®Google Scholar
• Zhabyeyev P, Chen X, Vanhaesebroeck B, et al. PI3Kα in cardioprotection: cytoskeleton, Late Na + current, and mechanism of arrhythmias. Channels. 2019;13(1):520–532.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG. The extracellular matrix in ischemic and nonischemic heart failure. Circ Res. 2019;125(1):117–146.
   PubMed Web of Science ®Google Scholar
• Patel VB, Zhabyeyev P, Chen X, et al. PI3Kα-regulated gelsolin activity is a critical determinant of cardiac cytoskeletal remodeling and heart disease. Nat Commun. 2018;9(1):5390.
   PubMedGoogle Scholar
• Lichter JG, Carruth E, Chelsea Mitchell AS, et al. Remodeling of the sarcomeric cytoskeleton in cardiac ventricular myocytes during heart failure and after cardiac resynchronization therapy. J Mol Cell Cardiol. 2014;72(July):186–195.
   PubMedGoogle Scholar
• Hein S. The role of the cytoskeleton in heart failure. Cardiovasc Res. 2000;45(2):273–278.
   PubMed Web of Science ®Google Scholar
• Ali H, Braga L, Giacca M. Cardiac regeneration and remodelling of the cardiomyocyte cytoarchitecture. FEBS J. 2020;287(3):417–438.
   PubMed Web of Science ®Google Scholar
• Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015;26(6):673–685.
   PubMed Web of Science ®Google Scholar
• Fahed AC, Jang I-K. Plaque erosion and acute coronary syndromes: phenotype, molecular characteristics and future directions. Nat Rev Cardiol. 2021 May;18(10):724–734.
   PubMed Web of Science ®Google Scholar
• Quillard T, Franck G, Mawson T, et al. Mechanisms of erosion of atherosclerotic plaques. Curr Opin Lipidol. 2017;28(5):434–441.
   PubMed Web of Science ®Google Scholar
• Nachtigal P, Rathouska J, Strasky Z. The role of endoglin in atherosclerosis. Atherosclerosis. 2012;224(1):4–11.
   PubMed Web of Science ®Google Scholar
• Garzon-Martinez M, Perretta-Tejedor N, Garcia-Ortiz L, et al. Association of Alk1 and endoglin polymorphisms with cardiovascular damage. Sci Rep. 2020;10(1):9383.
   PubMed Web of Science ®Google Scholar
• Saita E, Miura K, Suzuki-Sugihara N, et al. Plasma soluble endoglin levels are inversely associated with the severity of coronary atherosclerosis—brief report. Arterioscler Thromb Vasc Biol. 2017;37(1):49–52.
   PubMed Web of Science ®Google Scholar
• Liu R, Jin J-P. Deletion of Calponin 2 in macrophages alters cytoskeleton-based functions and attenuates the development of atherosclerosis. J Mol Cell Cardiol. 2016;99(October):87–99.
   PubMedGoogle Scholar
• Stakhneva EM, Meshcheryakova IA, Demidov EA, et al. A proteomic study of atherosclerotic plaques in men with coronary atherosclerosis. Diagnostics. 2019;9(4):177.
   Web of Science ®Google Scholar
• Rickel AP, Sanyour HJ, Leyda NA, et al. Extracellular matrix proteins and substrate stiffness synergistically regulate vascular smooth muscle cell migration and cortical cytoskeleton organization. ACS Appl Bio Mater. 2020;3(4):2360–2369.
   PubMedGoogle Scholar
• Xie S-A, Zhang T, Wang J, et al. Matrix stiffness determines the phenotype of vascular smooth muscle cell in vitro and in vivo: role of DNA methyltransferase 1. Biomaterials. 2018;155(February):203–216.
   PubMedGoogle Scholar
• Lyle AN, Robert Taylor W. The pathophysiological basis of vascular disease. Lab Invest. 2019;99(3):284–289.
   PubMed Web of Science ®Google Scholar
• Xu Q, Huff LP, Fujii M, et al. Redox regulation of the actin cytoskeleton and its role in the vascular system. Free Radic Biol Med. 2017;109(August):84–107.
   PubMedGoogle Scholar
• Elsafadi M, Manikandan M, Dawud RA, et al. Transgelin is a TGFβ-inducible gene that regulates osteoblastic and adipogenic differentiation of human skeletal stem cells through actin cytoskeleston organization. Cell Death Dis. 2016;7(8):e2321–e2321.
   PubMed Web of Science ®Google Scholar
• Doradla P, Otsuka K, Nadkarni A, et al. Biomechanical stress profiling of coronary atherosclerosis. JACC Cardiovasc Imaging. 2020;13(3):804–816.
   PubMed Web of Science ®Google Scholar
• Wang Z-Q, Jing L-L, Yan J-C, et al. Role of AGEs in the progression and regression of atherosclerotic plaques. Glycoconj J. 2018;35(5):443–450.
   PubMed Web of Science ®Google Scholar
• Soehnlein O, Libby P. Targeting inflammation in atherosclerosis — from experimental insights to the clinic. Nat Rev Drug Discov. 2021;20(8):589–610.
   PubMed Web of Science ®Google Scholar
• Gillette TG. HDAC Inhibition in the Heart: erasing Hidden Fibrosis. Circulation. 2021;143(19):1891–1893.
   PubMed Web of Science ®Google Scholar
• Hedhli N, Russell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev. 2012;7(4):221–233.
   Google Scholar
• Lee Y, Gustafsson ÅB. Role of apoptosis in cardiovascular disease. Apoptosis. 2009;14(4):536–548.
   PubMed Web of Science ®Google Scholar
• Kang PM, Yue P, Izumo S. New insights into the role of apoptosis in cardiovascular disease. Circ J. 2002;66(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sayen MR, Gustafsson ÅB, Sussman MA, et al. Calcineurin transgenic mice have mitochondrial dysfunction and elevated superoxide production. Am J Physiol Cell Physiol. 2003;284(2):C562–70.
   PubMed Web of Science ®Google Scholar
• Wang J, Silva JP, Gustafsson CM, et al. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc Nat Acad Sci. 2001;98(7):4038–4043.
   PubMed Web of Science ®Google Scholar
• Suria H, Chau LA, Negrou E, et al. Cytoskeletal disruption induces T cell apoptosis by a caspase-3 mediated mechanism. Life Sci. 1999;65(25):2697–2707.
   PubMed Web of Science ®Google Scholar
• Richter M, Kostin S. The failing human heart is characterized by decreased numbers of telocytes as result of apoptosis and altered extracellular matrix composition. J Cell Mol Med. 2015;19(11):2597–2606.
   PubMed Web of Science ®Google Scholar
• Nataatmadja M, West M, West J. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation. 2003;108(90101):329II–334.
   Google Scholar
• Fan Z, Chunyu L, Qin C, et al. Role of the PI3K/AKT pathway in modulating cytoskeleton rearrangements and phenotype switching in rat pulmonary arterial vascular smooth muscle cells. DNA Cell Biol. 2014;33(1):12–19.
   PubMed Web of Science ®Google Scholar
• Myers DL, Harmon KJ, Lindner V, et al. Alterations of arterial physiology in osteopontin-null mice. Arterioscler Thromb Vasc Biol. 2003;23(6):1021–1028.
   PubMed Web of Science ®Google Scholar
• Singh M, Foster CR, Dalal S, et al. Osteopontin: role in extracellular matrix deposition and myocardial remodeling Post-MI. J Mol Cell Cardiol. 2010;48(3):538–543.
   PubMed Web of Science ®Google Scholar
• Vetrone SA, Montecino-Rodriguez E, Kudryashova E, et al. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-β. J Clin Investig. 2009;119(6):1583–1594.
   PubMed Web of Science ®Google Scholar
• Plazyo O, Rong Liu M, Hossain M, et al. Deletion of Calponin 2 attenuates the development of calcific aortic valve disease in ApoE−/− mice. J Mol Cell Cardiol. 2018;121(August):233–241.
   PubMedGoogle Scholar
• Moazzem HM, Crish JF, Eckert RL, et al. H2-Calponin is regulated by mechanical tension and modifies the function of actin cytoskeleton. J Biol Chem. 2005;280(51):42442–42453.
   PubMed Web of Science ®Google Scholar
• Kapur N, Morine K, Letarte M. Endoglin: a critical mediator of cardiovascular health. Vasc Health Risk Manag. 2013 May;195. DOI:https://doi.org/10.2147/VHRM.S29144.
   Google Scholar
• Sanz-Rodriguez F, Guerrero-Esteo M, Botella L-M, et al. Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the lim family of proteins. J Biol Chem. 2004;279(31):32858–32868.
   PubMed Web of Science ®Google Scholar
• Africa F-L, Sanz-Rodriguez F, and Zarrabeitia R, et al. Blood outgrowth endothelial cells from hereditary haemorrhagic telangiectasia patients reveal abnormalities compatible with vascular lesions. Cardiovasc Res. 2005;235–48.
   PubMed Web of Science ®Google Scholar
• Obreo J, Díez-Marques L, Lamas S, et al. Endoglin expression regulates basal and TGF-Β1-induced extracellular matrix synthesis in cultured L6E9 myoblasts. Cell Physiol Biochem. 2004;14(4–6):301–310.
   PubMedGoogle Scholar
• Shimazaki M, Nakamura K, Kii I, et al. Periostin is essential for cardiac healingafter acute myocardial infarction. J Exp Med. 2008;205(2):295–303.
   PubMed Web of Science ®Google Scholar
• Oka T, Jian X, Kaiser RA, et al. Genetic manipulation of periostin expression reveals a role in cardiac hypertrophy and ventricular remodeling. Circ Res. 2007;101(3):313–321.
   PubMed Web of Science ®Google Scholar
• Nie X, Shen C, Tan J, et al. Periostin: a potential therapeutic target for pulmonary hypertension? Circ Res. 2020;127(9):1138–1152.
   PubMed Web of Science ®Google Scholar
• Snider P, Hinton RB, Moreno-Rodriguez RA, et al. Periostin is required for maturation and extracellular matrix stabilization of noncardiomyocyte lineages of the heart. Circ Res. 2008;102(7):752–760.
   PubMed Web of Science ®Google Scholar
• Li H, Bao M, Nie Y. Extracellular matrix–based biomaterials for cardiac regeneration and repair. Heart Fail Rev. April 2020. DOI:https://doi.org/10.1007/s10741-020-09953-9.
   Google Scholar
• Kühn B, Del Monte F, Hajjar RJ, et al. Periostin Induces proliferation of differentiated cardiomyocytes and promotes cardiac repair. Nat Med. 2007;13(8):962–969.
   PubMed Web of Science ®Google Scholar
• Bayomy AF, Bauer M, Qiu Y, et al. Regeneration in heart disease—is ECM the key? Life Sci. 2012;91(17–18):823–827.
   PubMed Web of Science ®Google Scholar
• Qiu Y, Bayomy AF, Gomez MV, et al. A role for matrix stiffness in the regulation of cardiac side population cell function. Am J Physiol Heart Circ Physiol. 2015;308(9):H990–97.
   PubMed Web of Science ®Google Scholar
• Derrick CJ, Noël ES. The ECM as a driver of heart development and repair. Development. 2021;148(5): dev191320. DOI:https://doi.org/10.1242/dev.191320.
   Google Scholar
• Steenman M, Lande G. Cardiac aging and heart disease in humans. Biophys Rev. 2017;9(2):131–137.
   PubMedGoogle Scholar
• Strait JB, Lakatta EG. Aging-associated cardiovascular changes and their relationship to heart failure. Heart Fail Clin. 2012;8(1):143–164.
   PubMed Web of Science ®Google Scholar
• Gulberk OS, Bahcecioglu G, Yue XS, et al. Effect of cellular and ECM aging on human IPSC-derived cardiomyocyte performance, maturity and senescence. Biomaterials. 2021;268(January):120554.
   PubMedGoogle Scholar
• Ma Z, Mao C, Jia Y, et al. Extracellular matrix dynamics in vascular remodeling. Am J Physiol Cell Physiol. 2020;319(3):C481–99.
   PubMed Web of Science ®Google Scholar
• Xia Y, Dobaczewski M, Gonzalez-Quesada C, et al. Endogenous Thrombospondin 1 protects the pressure-overloaded myocardium by modulating fibroblast phenotype and matrix metabolism. Hypertension. 2011;58(5):902–911.
   PubMed Web of Science ®Google Scholar
• Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous Thrombospondin-1 in preventing expansion of healing myocardial infarcts. Circulation. 2005;111(22):2935–2942.
   PubMed Web of Science ®Google Scholar
• Midwood KS, Orend G. The role of Tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal. 2009;3(3–4):287–310.
   PubMed Web of Science ®Google Scholar
• Gellen B, Thorin-Trescases N, Thorin E, et al.; on behalf of the SURDIAGENE Study group. Serum Tenascin-C is independently associated with increased major adverse cardiovascular events and death in individuals with type 2 diabetes: a french prospective cohort. Diabetologia. 2020;63(5):915–923.
   PubMed Web of Science ®Google Scholar
• Imanaka-Yoshida K, Tawara I, Yoshida T. Tenascin-C in cardiac disease: a sophisticated controller of inflammation, repair, and fibrosis. Am J Physiol Cell Physiol. 2020;319(5):C781–96.
   PubMed Web of Science ®Google Scholar
• Wenk MB, Midwood KS, Schwarzbauer JE. Tenascin-C suppresses Rho activation. J Cell Biol. 2000;150(4):913–920.
   PubMed Web of Science ®Google Scholar
• Sato A, Aonuma K, Imanaka-Yoshida K, et al. Serum Tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol. 2006;47(11):2319–2325.
   PubMed Web of Science ®Google Scholar
• Martin-Lorenzo M, Laura Gonzalez-Calero AS, Maroto PJ, et al. Cytoskeleton deregulation and impairment in amino acids and energy metabolism in early atherosclerosis at aortic tissue with reflection in plasma. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2016;1862(4):725–732.
   PubMed Web of Science ®Google Scholar
• Mao Z, Fen W, Shan Y. Identification of key genes and MiRNAs associated with carotid atherosclerosis based on MRNA-seq data:. Medicine (Baltimore). 2018;97(13):e9832.
   PubMed Web of Science ®Google Scholar
• Eslava-Alcon S, Extremera-García MJ, González-Rovira A, et al. Molecular signatures of atherosclerotic plaques: an up-dated panel of protein related markers. J Proteomics. 2020;221(June):103757.
   PubMedGoogle Scholar
• Hsu J, Gore-Panter S, Tchou G, et al. Genetic control of left atrial gene expression yields insights into the genetic susceptibility for atrial fibrillation. Circ Genomic Precis Med. 2018;11(3). DOI:https://doi.org/10.1161/CIRCGEN.118.002107
   Google Scholar
• Wain LV. Rare variants and cardiovascular disease. Brief Funct Genomics. 2014;13(5):384–391.
   PubMed Web of Science ®Google Scholar
• Sequeira V, Nijenkamp LLAM, Regan JA, et al. The physiological role of cardiac cytoskeleton and its alterations in heart failure. Biochim Biophys Acta - Biomembr. 2014;1838(2):700–722.
   Web of Science ®Google Scholar
• Chen J, Chien KR. Complexity in simplicity: monogenic disorders and complex cardiomyopathies. J Clin Investig. 1999;103(11):1483–1485.
   PubMed Web of Science ®Google Scholar
• Hafiane A. Vulnerable Plaque, characteristics, detection, and potential therapies. J Cardiovasc Dev Dis. 2019;6(3):26.
   Web of Science ®Google Scholar
• Johnson KW, Shameer K, Glicksberg BS, et al. Enabling precision cardiology through multiscale biology and systems medicine. JACC. 2017;2(3):311–327.
   Google Scholar
• Napoli C, Crudele V, Soricelli A, et al. Primary prevention of atherosclerosis: a clinical challenge for the reversal of epigenetic mechanisms? Circulation. 2012;125(19):2363–2373.
   PubMed Web of Science ®Google Scholar
• Colpaert RMW, Calore M. Epigenetics and MicroRNAs in cardiovascular diseases. Genomics. 2021;113(2):540–551.
   PubMed Web of Science ®Google Scholar
• Rosa-Garrido M, Chapski DJ, Schmitt AD, et al. High-resolution mapping of chromatin conformation in cardiac myocytes reveals structural remodeling of the epigenome in heart failure. Circulation. 2017;136(17):1613–1625.
   PubMed Web of Science ®Google Scholar
• Roberts LB, Kapoor P, Howard JK, et al. An update on the roles of immune system-derived MicroRNAs in cardiovascular diseases. Cardiovasc Res. 2021;117(12):2434–2449.
   PubMed Web of Science ®Google Scholar
• Afonso MS, Sharma M, Schlegel M, et al. MiR-33 silencing reprograms the immune cell landscape in atherosclerotic plaques. Circ Res. 2021;128(8):1122–1138.
   PubMed Web of Science ®Google Scholar
• Liu A, Liu Y, Bin L, et al. Role of MiR‐223‐3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway. Cell Prolif. 2019;52(2):e12550.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang K, Mao W. Inhibition of MiR‑34a prevents endothelial cell apoptosis by directly targeting HDAC1 in the setting of atherosclerosis. Mol Med Rep. 2018 January;17(3):4645–4650.
   PubMed Web of Science ®Google Scholar
• Yan M, Chen C, Gong W, et al. MiR-21-3p regulates cardiac hypertrophic response by targeting Histone Deacetylase-8. Cardiovasc Res. 2015;105(3):340–352.
   PubMed Web of Science ®Google Scholar
• Cheng H-P, Gong D, Zhao Z-W, et al. MicroRNA-182 promotes lipoprotein lipase expression and atherogenesisby targeting Histone Deacetylase 9 in Apolipoprotein E-knockout mice. Circ J. 2018;82(1):28–38.
   Web of Science ®Google Scholar
• Souilhol C, Serbanovic-Canic J, Maria Fragiadaki TJ, et al. Endothelial responses to shear stress in atherosclerosis: a novel role for developmental genes. Nat Rev Cardiol. 2020;17(1):52–63.
   PubMed Web of Science ®Google Scholar
• Li J, Brundel BJJM, Zhang D. n.d. ESC | ESC CONGRESS 2020 - the digital experience | preservation of the microtubule network to beat atrial fibrillation: role of SR-mitochondrial contacts. ESC2020 - The Digital Experience. [cited 2020 Dec 19]. https://programme.escardio.org/ESC2020/Abstracts/220247-preservation-of-the-microtubule-network-to-beat-atrial-fibrillation-role-of-sr-mitochondrial-contacts?r=/ESC2020/On-Demand?s%3D%24expression%3Dmicrotubule
   Google Scholar
• Caporizzo MA, Chen CY, Prosser BL. Cardiac microtubules in health and heart disease. Exp Biol Med. 2019;244(15):1255–1272.
   Web of Science ®Google Scholar
• Ridker PM. From CANTOS to CIRT to COLCOT to clinic: will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents? Circulation. 2020;141(10):787–789.
   PubMed Web of Science ®Google Scholar
• Imazio M, Nidorf M. Colchicine and the Heart. Eur Heart J. 2021;42(28):2745–2760. no. ehab221 (May).
   PubMed Web of Science ®Google Scholar
• Tardif J-C, Simon Kouz DD, Waters OF, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497–2505.
   PubMed Web of Science ®Google Scholar
• Bouabdallaoui N, Tardif J-C, Waters DD, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). Eur Heart J. 2020;41(42):4092–4099.
   PubMed Web of Science ®Google Scholar
• Opstal TSJ, Hoogeveen RM, Fiolet ATL, et al. Colchicine attenuates inflammation beyond the inflammasome in chronic coronary artery disease: a LoDoCo2 proteomic substudy. Circulation. 2020;142(20):1996–1998.
   PubMed Web of Science ®Google Scholar
• Nidorf SM, Fiolet ATL, Mosterd A, et al. Salem H.K. The. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838–1847.
   PubMed Web of Science ®Google Scholar
• Kampourakis T, Zhang X, Sun Y-B, et al. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament: myosin filament regulation in heart muscle. J Physiol. 2018;596(1):31–46.
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Diaz R, Felker GM, et al. Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure. N Engl J Med. November 2020; NEJMoa2025797. doi:https://doi.org/10.1056/NEJMoa2025797.
   Google Scholar
• Olivotto I, Oreziak A, Barriales-Villa R, et al. Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020;396(10253):759–769.
   PubMed Web of Science ®Google Scholar
• Bassat E, Mutlak YE, Genzelinakh A, et al. The extracellular matrix protein agrin promotes heart regeneration in mice. Nature. 2017;547(7662):179–184.
   PubMed Web of Science ®Google Scholar
• Zannad F, Alla F, Dousset B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure,” 7. n.d.
   Google Scholar
• Hutchinson KR, Stewart JA, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol. 2010;48(3):564–569.
   PubMed Web of Science ®Google Scholar
• Li Y, Gao S, Han Y, et al. Variants of focal adhesion scaffold genes cause thoracic aortic aneurysm. Circ Res. 2021;128(1):8–23.
   PubMed Web of Science ®Google Scholar
• López-Novoa JM, Bernabeu C. The physiological role of endoglin in the cardiovascular system. Am J Physiol Heart Circ Physiol. 2010;299(4):H959–74.
   PubMed Web of Science ®Google Scholar
• Michaelis M, Seyb K, Ansar S. Cytoskeletal Integrity as a Drug Target. Curr Alzheimer Res. 2005;2(2):227–229.
   PubMedGoogle Scholar
• Travers JG, Wennersten SA, Peña B, et al. HDAC inhibition reverses preexisting diastolic dysfunction and blocks covert extracellular matrix remodeling. Circulation. 2021;143(19):1874–1890.
   PubMed Web of Science ®Google Scholar
• Lizardi V, Carlos J, Jerome Baranger MB, et al. A guide for assessment of myocardial stiffness in health and disease. Nature Cardiovascular Research. 2022;1(1):8–22.
   Google Scholar
• Li H, Bao M, Nie Y. Extracellular matrix–based biomaterials for cardiac regeneration and repair. Heart Fail Rev. 2021;26(5):1231–1248.
   PubMed Web of Science ®Google Scholar
• Lemon DD, Horn TR, Cavasin MA, et al. Cardiac HDAC6 catalytic activity is induced in response to chronic hypertension. J Mol Cell Cardiol. 2011;51(1):41–50.
   PubMed Web of Science ®Google Scholar
• Markus W, Eaton Deborah M, Berretta Remus M, et al. HDAC inhibition improves cardiopulmonary function in a feline model of diastolic dysfunction. Sci Transl Med. 2020;12(525). eaay7205. doi:https://doi.org/10.1126/scitranslmed.aay7205.
   Google Scholar
• Geng Y-J, Azuma T, Tang JX, et al. Caspase-3-induced gelsolin fragmentation contributes to actin cytoskeletal collapse, nucleolysis, and apoptosis of vascular smooth muscle cells exposed to proinflammatory cytokines. Eur J Cell Biol. 1998;77(4):294–302.
   PubMed Web of Science ®Google Scholar